Nanosphere faces "period in purgatory" after "long-overdue" CEO change
This article was originally published in Clinica
Executive Summary
Molecular diagnostics company Nanosphere has appointed Michael McGarrity CEO, replacing William Moffitt, in a personnel overhaul that has also seen four board members resign. The changes were "necessary and long overdue" after a "track record littered with numerous operational disappointments", according to Jefferies analyst Jon Wood, who added that the "changes may very well be the perfect antidote to perennial under-performance". Even so, the firm's share "may see a period in purgatory" as "new leadership faces an uphill battle to re-gain investor trust", wrote the analyst. Nanosphere's shares are currently trading at around $2.64 on Nasdaq.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.